4.7 Review

Experimental rhinovirus infection in COPD: Implications for antiviral therapies

Journal

ANTIVIRAL RESEARCH
Volume 102, Issue -, Pages 95-105

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2013.12.006

Keywords

Chronic obstructive pulmonary disease (COPD); Exacerbations; Respiratory viruses; Rhinovirus

Funding

  1. Medical Research Council [G1000758B, G1000758] Funding Source: researchfish
  2. National Institute for Health Research [ACF-2012-21-016, CL-2008-21-014] Funding Source: researchfish
  3. Medical Research Council [G1000758] Funding Source: Medline

Ask authors/readers for more resources

Chronic obstructive pulmonary disease (COPD) is a major public health problem and will be one of the leading global causes of mortality over the coming decades. Much of the morbidity, mortality and health care costs of COPD are attributable to acute exacerbations, the commonest causes of which are respiratory infections. Respiratory viruses are frequently detected in COPD exacerbations but direct proof of a causative relationship has been lacking. We have developed a model of COPD exacerbation using experimental rhinovirus infection in COPD patients and this has established a causative relationship between virus infection and exacerbations. In addition it has determined some of the molecular mechanisms linking virus infections to COPD exacerbations and identified potential new therapeutic targets. This new data should stimulate research into the role of antiviral agents as potential treatments for COPD exacerbations. Testing of antiviral agents has been hampered by the lack of a small animal model for rhinovirus infection and experimental rhinovirus infection in healthy volunteers has been used to test treatments for the common cold. Experimental rhinovirus infection in COPD subjects offers the prospect of a model that can be used to evaluate the effects of new treatments for virus-induced COPD exacerbations, and provide essential data that can be used in making decisions regarding large scale clinical trials. (C) 2014 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available